《替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识》解读

Consensus interpretation on "Expert consensus on clinical application of tirofiban in atherosclerotic cerebrovascular disease"

血小板表面糖蛋白Ⅱb/Ⅲa受体是血小板聚集、血栓形成的最终共同通路,可特异性快速抑制血小板聚集。近年越来越多的证据支持糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班可以作为血栓栓塞性疾病的治疗选择,但其在临床实践中的应用经验仍相对不足。为了临床更合理、规范地应用替罗非班,中国卒中学会组织国内神经介入领域知名专家成立撰写委员会,制定了《替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识》,为替罗非班在脑血管病领域中的应用提供了临床经验和指导,并对医疗行为中安全、有效的用药提供了保障。

Platelet glycoprotein(GP)Ⅱb/Ⅲa receptor is the final common pathway of platelet aggregation and thrombosis,which can specifically and rapidly inhibit platelet aggregation.In recent years,more and more evidences support that tirofiban,a GPⅡb/Ⅲa receptor antagonist,can be used as a treatment option for thromboembolic diseases,but its application experience in clinical practice is still relatively insufficient.In order to apply tirofiban more reasonably and normatively in clinical practice,the Chinese Stroke Society organized a writing committee of well-known experts in the field of neurological intervention in China,and wrote the consensus of experts on the clinical application of tirofiban in atherosclerotic cerebrovascular diseases.It provides clinical experience and guidance for the application of tirofiban in the field of cerebrovascular disease,and guarantees the safe and effective use of drugs in medical behaviors.